Search
Results: 3
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.
Nancy J Newman, Patrick Yu-Wai-Man, Valerio Carelli, Mark L Moster, Valerie Biousse, Catherine Vignal-Clermont, Robert C Sergott, Thomas Klopstock, Alfredo A Sadun, Piero Barboni, Adam A DeBusk, Jean François Girmens, Günther Rudolph, Rustum Karanjia, Magali Taiel, Laure Blouin, Gerard Smits, Barrett Katz, José-Alain Sahel, LHON Study Group
Apr 15, 2021
PURPOSE: To evaluate the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON). DESIGN: RESCUE is a multicenter, randomized, double-masked...
Humphrey visual field perimetry Leber hereditary optic neuropathy Phase 3 randomized double-masked clinical trial Quality of life best-corrected visual acuity bilateral visual improvement Contrast Sensitivity EFFICACY intravitreal gene therapy retinal anatomic measures Safety Adolescent Adult Aged DNA Mitochondrial Dependovirus Double-Blind Method Electroretinography Female Follow-Up Studies Genetic Therapy Genetic Vectors Humans Intravitreal Injections Male Middle Aged Mutation Optic Atrophy Hereditary Leber Quality of life Time Factors Treatment Outcome Visual Acuity Visual Field Tests Visual Fields Young Adult
Differences in vision performance in different scenarios and implications for design.
Joy Goodman-Deane, Sam Waller, Keziah Latham, Holly Price, Raji Tenneti, P John Clarkson
Feb 03, 2016
Six-month Longitudinal Comparison of a Portable Tablet Perimeter With the Humphrey Field Analyzer.
Selwyn Marc Prea, Yu Xiang George Kong, Aditi Mehta, Mingguang He, Jonathan G Crowston, Vinay Gupta, Keith R Martin, Algis J Vingrys
Aug 03, 2018